Company news

Harmony Biosciences Holdings, Inc. news in 2024

Harmony Biosciences Holdings, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Harmony Biosciences to present at the 43rd annual j.p. morgan healthcare conference

December 17, 2024

Harmony Biosciences to participate in oppenheimer movers in rare disease summit

December 2, 2024

Harmony Biosciences to participate in upcoming investor conferences

November 20, 2024

Harmony Biosciences Holdings, Inc. Announces Pricing of Public Offering of Common Stock by Selling Shareholders

October 29, 2024

Harmony Biosciences reports strong third quarter 2024 financial results and highlights catalyst-rich, late-stage pipeline poised to deliver one or more new launches every year over next five years

October 28, 2024

Harmony Biosciences Holdings, Inc. Announces Commencement of Proposed Public Offering of Common Stock by Selling Shareholders

October 28, 2024

Harmony Biosciences to report third quarter 2024 financial results on October 29, 2024

October 15, 2024

Harmony Biosciences highlights new data, robust late-stage pipeline with near-term value creation opportunities and its bold new vision at investor day

September 30, 2024

Harmony Biosciences to host first Investor Day on October 1, 2024

September 25, 2024

Harmony Biosciences Reports Strong Second Quarter 2024 Financial Results and Advances Pitolisant High-Dose Program Toward Expected PDUFA Date in 2028

August 5, 2024

Harmony Biosciences to report second quarter 2024 financial results on August 6, 2024

July 22, 2024

Harmony Biosciences acknowledges U.S. food & Drug Administration (FDA) action denying the Citizen Petition for WAKIX® (pitolsiant)

June 24, 2024

Harmony Biosciences receives U.S. food and Drug Administration approval for WAKIX® (pitolisant) in pediatric patients with narcolepsy

June 23, 2024

Harmony Biosciences presents positive data for pitolisant in the treatment of excessive Daytime Sleepiness and fatigue in Myotonic dystrophy Type 1

June 4, 2024

Harmony Biosciences to participate in goldman sachs 45th annual global healthcare conference

May 27, 2024

Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wake Leadership and Diversifies Into Rare Epilepsy

April 29, 2024

Harmony Biosciences Acquires Epygenix Therapeutics, Inc., Adding Late-Stage Epilepsy Franchise to Growing Pipeline of Innovative CNS Assets

April 29, 2024

Harmony Biosciences to report first quarter 2024 financial results on April 30, 2024

April 15, 2024

Harmony Biosciences announces exclusive agreement to develop and commercialize TPM-1116, a highly potent and selective oral orexin-2 receptor agonist

April 10, 2024

Harmony Biosciences initiates global Phase 3 registrational trial (TEMPO study) of pitolisant in patients with Prader-Willi syndrome

April 2, 2024

Harmony Biosciences to participate in 23rd annual needham virtual healthcare conference

March 25, 2024

Harmony Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

February 21, 2024

U.S. food and Drug Administration grants priority review to Harmony Biosciences' application for WAKIX® (pitolisant) in pediatric narcolepsy

February 20, 2024

Harmony Biosciences receives U.S. food and Drug Administration Orphan Drug designation for pitolisant in Prader-Willi syndrome

February 19, 2024

Harmony Biosciences to report fourth quarter and full year 2023 financial results on February 22, 2024

February 7, 2024

Harmony Biosciences preliminary unaudited fourth quarter and full year 2023 net product revenue increases more than 30 percent; provides 2024 net product revenue guidance

January 7, 2024

Harmony Biosciences to present at the 42nd annual j.p. morgan healthcare conference

January 2, 2024

Calls in 2024

Decks in 2024